Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956214 | 1.00 | TERT (0.47) | TERTERN1CCR1RXRALMNA | |
| SCHEMBL3294386 | 0.80 | TSHR (0.46) | RXRALMNATSHRALDH1A1MAPT | |
| SCHEMBL9000446 | 0.79 | KMT2A (0.41) | RXRALMNATSHRALDH1A1NPC1 | |
| SCHEMBL303150 | 0.75 | CCR1 (0.55) | TERTCCR1LMNAALDH1A1TDP1 | |
| SCHEMBL3144065 | 0.74 | LMNA (0.41) | CCR1LMNATSHRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL27613798 | 0.73 | CCR1 (0.52) | TERTCCR1LMNAALDH1A1TDP1 | |
| SCHEMBL17598049 | 0.72 | ERN1 (0.42) | ERN1RXRALMNAALDH1A1NPC1 | |
| SCHEMBL19456924 | 0.72 | TERT (0.53) | TERTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL873623 | 0.71 | TSHR (0.43) | LMNATSHRALDH1A1MAPTTDP1 | |
| SCHEMBL3865531 | 0.71 | GPR35 (0.45) | ERN1LMNATSHRALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101367891-B | Nitrogen-nitrogen-oxygen nickel complex catalytic system for addition polymerisation of norbornene and its derivant, preparation method and uses thereof | UNIV SOUTH CENTRAL NATIONALITI | 2010-09-08 | — | — | CN | claimed |
| CN-101367891-A | Nitrogen-nitrogen-oxygen nickel complex catalytic system for addition polymerisation of norbornene and its derivant, preparation method and uses thereof | SOUTH CENTRAL UNIVERSITY FOR N (CN) | 2009-02-18 | — | — | CN | claimed |
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| CN-101367891-B | Nitrogen-nitrogen-oxygen nickel complex catalytic system for addition polymerisation of norbornene and its derivant, preparation method and uses thereof | UNIV SOUTH CENTRAL NATIONALITI | 2010-09-08 | — | — | CN | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2167465-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Boehringer Ingelheim International GmbH (DE) | 2010-03-31 | — | — | EP | disclosed |
| CN-101367891-A | Nitrogen-nitrogen-oxygen nickel complex catalytic system for addition polymerisation of norbornene and its derivant, preparation method and uses thereof | SOUTH CENTRAL UNIVERSITY FOR N (CN) | 2009-02-18 | — | — | CN | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | TERT 1999/4885ERN1 3220/4885CCR1 1197/4885 |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | TERT 1999/4885ERN1 3220/4885CCR1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.